Sullivan Timothy Eugene
Chief Financial Officer
Sullivan Timothy Eugene has filed 8 SEC Form 4 filings (23 transaction rows) across 1 company, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: May 14, 2026.
On the most recent filing, Sullivan Timothy Eugene is listed as Chief Financial Officer at Apellis Pharmaceuticals, Inc. Inside the rolling window, Sullivan Timothy Eugene reported no open-market purchases and 4 open-market sales totaling $647K in APLS. The largest disclosed transaction in the window is a sale of 10,000 APLS shares on Oct 21, 2025, worth $280K.
Companies traded
Other insiders at APLS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$647K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
Frequently asked questions
How many SEC Form 4 filings has Sullivan Timothy Eugene made?
Sullivan Timothy Eugene has filed 8 SEC Form 4 filings (23 transaction rows) across 1 company since 2025.
Which companies does Sullivan Timothy Eugene trade?
Sullivan Timothy Eugene has filed SEC Form 4 disclosures for 1 company, including APLS.
When was Sullivan Timothy Eugene's most recent SEC Form 4 filing?
Sullivan Timothy Eugene's most recent SEC Form 4 filing on Tracefour is dated May 14, 2026.
What is Sullivan Timothy Eugene's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Sullivan Timothy Eugene is listed as Chief Financial Officer.
What is Sullivan Timothy Eugene's total buy and sell value in the current window?
Inside the rolling retention window, Sullivan Timothy Eugene bought $0 and sold $647K based on SEC Form 4 filings.
What was Sullivan Timothy Eugene's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,000 APLS shares on 2025-10-21, worth $280K, per SEC Form 4 filings.